Cost Drivers in Patients with Classic Congenital Adrenal Hyperplasia (CAH)

Author(s)

Farrar M1, O’Donoghue C1, Paiewonsky E1, Yonan C1, Nathan R2, Pfeffer D2, Tiwari V2, Shripathi P2, Russo P3
1Neurocrine Biosciences, Inc., San Diego, CA, USA, 2EVERSANA Life Sciences Inc., Milwaukee, WI, USA, 3Spring Hills Post-Acute Care Programs, Population Health-MSO, Edison, NJ, USA

Presentation Documents

OBJECTIVES: Classic CAH is a rare condition characterized by cortisol deficiency and androgen excess, typically requiring treatment with supraphysiologic doses of glucocorticoids. This study evaluated the costs and identified key cost drivers for classic CAH in the United States (US).

METHODS: Real-world administrative claims data from IBM MarketScan Research Databases, with de-identified data of >200 million patients in the US between Jan 2006 and Dec 2020, was retrospectively analyzed for cost of care. The CAH cohort for analysis included patients with ICD codes (255.2, E25.0, or E25.9) and with either of the two glucocorticoid sensitivities (60% proportion of days covered or five glucocorticoid prescriptions). Patients were stratified into low, medium, and high-cost groups as per equal cumulative costs distribution in a 4-year period (±2 years from index date). Costs were calculated by patient segment, demographics, facility, diagnoses, procedures, and drugs.

RESULTS: The study included 7,150 patients with classic CAH (41.8% pediatric, 58.2% adults, 40% female) ages <1-90 years. High-cost patients (per member per year (PMPY) costs $81,020; n=209) accounted for 2.9% of classic CAH patients, 12% were medium-cost (PMPY=$22,012; n=855), and 85% were low-cost patients (PMPY=$5,822; n=6,073). High-cost patients of all ages were more likely to visit the emergency department (94%, vs. 82% medium-cost and 55% low-cost patients). In addition, 89% of high-cost patients had inpatient stays compared to 67% medium and 25% low-cost patients. High-cost patients were more likely to have fatigue/malaise (64%) compared to medium-cost (45%) and low-cost (21%) patients. Roughly 15% of patients (high and medium-cost cohorts; n=1,064) accounted for two thirds of the total costs paid to the providers.

CONCLUSIONS: Key cost drivers in the care of CAH patients include inpatient hospitalizations, ancillary services, and diagnostic procedures. Current and emerging therapies for CAH should be evaluated for their potential to impact these cost drivers.

Conference/Value in Health Info

2022-05, ISPOR 2022, Washington, DC, USA

Code

EE126

Topic

Economic Evaluation

Disease

No Additional Disease & Conditions/Specialized Treatment Areas

Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×